Artificial intelligence tool for detecting liver damage in primary care
Part of Digestive system clinical trials.
This study is testing a new AI tool called FibroX that helps doctors identify liver damage earlier. If you join, you will review simulated patient charts to see how the tool helps you make decisions about liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a doctor, nurse practitioner, or physician assistant.
- You currently see adult patients in a primary care clinic at least half of your work time.
- You are part of one of the participating clinics (academic, community, or a health center that gives care regardless of ability to pay).
- You are available to do two practice sessions using simulated electronic health records.
- You have not been involved in creating or testing the FibroX tool before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests electronic tools to help doctors identify and care for patients with steatotic liver disease (fatty liver). If you have risk factors like diabetes or elevated liver enzymes, this trial may help improve your care.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study tests a new ultrasound device that uses sound waves to measure fat in the liver without needles or surgery. It is for people with a type of fatty liver disease called MASLD or MASH, who are already getting an MRI to check their liver.
This study tests a new device called LiverScope® that scans your liver to detect fatty liver disease (MASLD). The scan uses special imaging technology and may help doctors diagnose liver disease more quickly and accurately.
This study tests a new screening tool to find advanced liver scarring in people with liver disease linked to diabetes. It helps doctors decide who needs more tests or specialist care.
This study uses artificial intelligence to help doctors identify fatty liver disease from CT scans you may already be having. If eligible, you'll have some blood tests and possibly an ultrasound or MRI to confirm liver health, helping catch liver disease early.
Hear when a new MASLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.